Based on this, the hypothesis of the present study is that tocilizumab (TCZ) canprevent AKI through its inhibitory action on IL-6, interfering with bothantigen-specific immune responses and inflammatory processes, and acting as a keyagent in the early stage of inflammation(8). Here, IL6 is linked to acute kidney injury.